This study was designed to look at safety aspects and effects of repeat inhaled doses of GW870086X in mild asthmatics to develop this drug for its use in asthma and chronic obstructive pulmonary disease (COPD)

Inclusion criteria:

• Male subjects aged 18-55
• Documented history of bronchial asthma diagnosed at least 6 months ago.
• Only being treated with short-acting beta-2-agonist therapy e.g. Ventolin
• Documented sensitivity to adenosine mono phosphate (AMP) at screening visit
• Demonstrate repeatable and reproducable response to inhaled AMP at the run-in visit

Exclusion criteria:

• Any significant illness or disease
• History of life threatening asthma
• History of respiratory tract infection
• Subjects who take medication for their asthma, or other conditions, not compatible with this study.
• Smoker
• Subjects who are oversensitive to corticosteroids
• History of drug or alcohol abuse
• Donated blood within last 3 months
• Been involved in another clinical trial during the last 3 months
• Subjects who work night shifts
• Subjects who are undergoing de-sensitisation therapy